Business
Intensity Therapeutics, The Ottawa Hospital and Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers
Significant Necrosis Demonstrated in Invasive Ductal and Lobular Cancers, Which are Normally Resistant to Chemotherapy. Significant Necrosis from a Single
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"Significant Necrosis Demonstrated in Invasive Ductal and Lobular Cancers, Which are Normally Resistant to Chemotherapy.\nSignificant Necrosis from a Single Injection of up to 100% of a Tumor was Observed During the Trial\nWithin the Tumor Microenvironment, There was a Relative Increase in Abundance of CD8 Memory T, CD4 Naïve and B Cells Post-Treatment\nNo Surgery was Delayed or Cancelled, and No Surgical Procedure Altered\nResults to be Presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting\nWESTPORT, Conn. and OTTAWA, ON and TORONTO, Nov. 10, 2022 /PRNewswire/ -- Intensity Therapeutics, Inc. (\"Intensity\"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, along with The Ottawa Hospital and Ontario Institute of Cancer Research (\"OICR\"), will present updated data from the INVINCIBLE study, a randomized, phase 2 presurgical window of opportunity trial for Intensity's intratumoral INT230-6 comprising SHAO (dispersion enhancer), vinblastine (VIN) and cisplatin (CIS), that is evaluating clinical and biological effects in patients with early-stage operable breast cancer. The study, to be presented today at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting being held in Boston and virtually from November 8-12, 2022, will report data demonstrating efficacy and tolerability of INT230-6.\nAbstract Number: 545Title: A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory effects of Intratumoral INT230-6 (Cisplatin, Vinblastine) in Early Stage Breast Cancer: the INVINCIBLE TrialFirst Author: Angel Arnaout, M.D., FACSSession Date and Time: Thursday, November 10, 2022, 9:00 am - 9:00 pm ESTLocation: Hall C; In-Person & On Demand\nCopies of the presentation materials will be available on the Intensity Therapeutics website on the publications and posters page.\n\"For a breast cancer patient, the typical waiting period of 2-6 weeks from diagnosis to surgery is a very anxious time. Surgeons and patients feel helpless, as there are currently no therapeutic options for the patient during this time,\" said Angel Arnaout, M.D., Scientist and Surgical Oncologist at the Ottawa Hospital, and Professor of S...